ArticleWorld journal of gastroenterology2013
Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug.
Article in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 56 citations in OpenAlex.
- Non-celiac Enteropathies.Current gastroenterology reports · 2025Review
- Drug-induced mucosal alterations observed during esophagogastroduodenoscopy.World journal of gastroenterology · 2024Review
- A Rare Case of Olmesartan-Associated Enteropathy Successfully Managed With Steroid Taper.Cureus · 2023Article
- Collagenous sprue: a rare cause of watery diarrhea and villous atrophy - case report.Gastroenterology and hepatology from bed to bench · 2023Article
- Coeliac disease enteropathy and symptoms may be aggravated by angiotensin receptor blockers in patients on a gluten-free diet.United European gastroenterology journal · 2021Article
- Cutaneous ulcers in association with sprue-like enteropathy secondary to Losartan.Clinical case reports · 2021Article
- European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations.United European gastroenterology journal · 2021Article
- Severe Sprue-Like Enteropathy and Colitis due to Olmesartan: Lessons Learned From a Rare Entity.Gastroenterology research · 2020Article
- Article
- Telmisartan-induced sprue-like enteropathy: a case report.European journal of hospital pharmacy : science and practice · 2020Article
- Olmesartan Associated Enteropathy: A Rare Underdiagnosed Cause of Diarrhea and Weight Loss.The American journal of case reports · 2019Article
- Acute Gastrointestinal Bleeding in Olmesartan-Associated Collagenous Gastroduodenitis: A Potential Endoscopic Complication.Case reports in gastrointestinal medicine · 2018Article
- A Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan.Journal of clinical medicine research · 2017Article
- Small bowel enteropathy associated with olmesartan medoxomil treatment.Annals of gastroenterology · 2017Article
- The first cases of collagenous sprue successfully treated with thioguanine.BMJ open gastroenterology · 2016Article
- Immunopathogenesis of olmesartan-associated enteropathy.Alimentary pharmacology & therapeutics · 2015Article
- A Case of Severe Sprue-Like Enteropathy Associated With Valsartan.ACG case reports journal · 2015Article
- Olmesartan-related sprue-like enteropathy.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2014Article
- Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study.Mayo Clinic proceedings · 2014Article
- Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block.GE Portuguese journal of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collagenous sprue (CS) is a pattern of small-bowel injury characterized histologically by marked villous blunting, intraepithelial lymphocytes, and thickened sub-epithelial collagen table. Clinically, patients present with diarrhea, abdominal pain, malabsorption, and weight loss. Gluten intolerance is the most common cause of villous blunting in the duodenum; however, in a recent case series by the Mayo Clinic, it has been reported that olmesartan can have a similar effect. In this case report, a 62-year-old female with a history of hypothyroidism and hypertension managed for several years with olmesartan presented with abdominal pain, weight loss, and nausea. Despite compliance to a gluten-free diet, the patient's symptoms worsened, losing 20 pounds in 3 wk. Endoscopy showed thickening, scalloping, and mosaiform changes of the duodenal mucosa. The biopsy showed CS characterized by complete villous atrophy, lymphocytosis, and thickened sub-epithelial collagen table. After 2 mo cessation of olmesartan, the patient's symptoms improved, and follow-up endoscopy was normal with complete villous regeneration. These findings suggest that olmesartan was a contributing factor in the etiology of this patient's CS. Clinicians should be aware of the possibility of drug-induced CS and potential reversibility after discontinuation of medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.